← Leaderboards
Abraham Pinter
Rutgers Biomedical And Health Sciences
$23,454,706
Attributed
$25,238,686
Total exposure
15
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$40,492,932 · 16
By mechanism
P01$18,661,554 · 5
R01$13,609,465 · 4
U01$3,254,190 · 1
R44$2,992,950 · 1
R56$1,276,313 · 2
R21$698,460 · 3
Top collaborators
- Christopher Marshall3 shared
- Padmini Salgame2 shared
- Yingda Linda Xie2 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Padmini Salgame$42,479,907
- David Alland$97,558,393
- John R. Chan$24,248,523
- Yingda Linda Xie$3,587,896
Others in their field
Top investigators on “Epitopes”
- Lawrence Corey · Fred Hutchinson Cancer Center$261,200,380
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$255,239,983
- Dennis R. Burton · Scripps Research Institute$109,374,382
- Barton F Haynes · Duke University$108,968,244
- Alessandro Sette · La Jolla Institute For Immunology$86,747,756
- Dan H. Barouch · Fred Hutchinson Cancer Center$81,679,346
Research focus
EpitopesHiv-1AntigensHiv Envelope Protein Gp120SpecificitySerumNeutralizing AntibodyAntibodiesPropertyReagentStructureBaseBinding (Molecular Function)ImmunogenicityCohortProgramsVariantB-LymphocytesMasksVaccinesResistanceSiteCollaborationsMaps
Grant awards (61)
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$733,212
R01 · FY2024 · AI · contact PI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$747,342
R01 · FY2023 · AI · contact PI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$196,250
R21 · FY2023 · AI
Development of a highly-sensitive urine test for tuberculosis (TB) that detects diverse forms of urinary TB lipoarabinomannan (uLAM)$783,218
R56 · FY2022 · AI · contact PI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$747,342
R01 · FY2022 · AI · contact PI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$235,007
R21 · FY2022 · AI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$219,988
R01 · FY2022 · AI · contact PI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$747,759
R01 · FY2021 · AI · contact PI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen$729,737
R01 · FY2020 · AI · contact PI
Conformational Stabilization of the HIV-1 Env Trimer$999,646
R44 · FY2015 · AI
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120$792,991
R01 · FY2015 · AI · contact PI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,947,908
P01 · FY2014 · AI · contact PI
Conformational Stabilization of the HIV-1 Env Trimer$993,663
R44 · FY2014 · AI
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120$800,581
R01 · FY2014 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$490,453
P01 · FY2014 · AI · contact PI
Administrative Core$195,072
P01 · FY2014 · AI · contact PI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,909,196
P01 · FY2013 · AI · contact PI
Conformational Stabilization of the HIV-1 Env Trimer$999,641
R44 · FY2013 · AI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$565,927
P01 · FY2013 · AI · contact PI
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120$515,450
R01 · FY2013 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$433,320
P01 · FY2013 · AI · contact PI
Administrative Core$181,772
P01 · FY2013 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$39,272
P01 · FY2013 · AI · contact PI
Administrative Core$16,473
P01 · FY2013 · AI · contact PI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$3,103,251
P01 · FY2012 · AI · contact PI
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120$562,814
R01 · FY2012 · AI · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$483,963
U01 · FY2012 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$468,429
P01 · FY2012 · AI · contact PI
Administrative Core$243,903
P01 · FY2012 · AI · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$93,955
U01 · FY2012 · AI · contact PI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,942,662
P01 · FY2011 · AI · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$587,807
U01 · FY2011 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$422,425
P01 · FY2011 · AI · contact PI
Administrative Core$238,167
P01 · FY2011 · AI · contact PI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,785,302
P01 · FY2010 · AI · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$605,906
U01 · FY2010 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$534,132
R01 · FY2010 · AI · contact PI
Characterization of sequence specificities and structures of QNEs$428,047
P01 · FY2010 · AI · contact PI
Administrative Core$249,975
P01 · FY2010 · AI · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$834,555
U01 · FY2009 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$641,803
R01 · FY2009 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$523,908
R01 · FY2009 · AI · contact PI
HTS assays for reagents capable of unmasking conserved neutralization sites in HI$156,000
R21 · FY2009 · NS · contact PI
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolates$648,004
U01 · FY2008 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$508,749
R01 · FY2008 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$503,596
R01 · FY2007 · AI · contact PI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$345,702
R01 · FY2006 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$324,070
R01 · FY2006 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$178,545
R01 · FY2006 · AI · contact PI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$34,135
R01 · FY2006 · AI · contact PI
Antigenic properties of the V1/V2 domain of HIV-1 gp120$493,095
R56 · FY2005 · AI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$389,000
R01 · FY2005 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$416,395
R01 · FY2004 · AI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$389,000
R01 · FY2004 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$404,235
R01 · FY2003 · AI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$389,000
R01 · FY2003 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$392,429
R01 · FY2002 · AI
Novel HIV Neutralizing Human MAbs from Transgenic Mice$389,000
R01 · FY2002 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$380,968
R01 · FY2001 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$267,582
R01 · FY2000 · AI
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120$111,203
R21 · FY2000 · AI